

Roberto A Leon-Ferre

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7465428/publications.pdf>

Version: 2024-02-01

31
papers

792
citations

686830

13
h-index

525886

27
g-index

31
all docs

31
docs citations

31
times ranked

1341
citing authors

#	ARTICLE	IF	CITATIONS
1	The path to a better biomarker: application of a risk management framework for the implementation of PD-L1 and TILs as immunology biomarkers in breast cancer clinical trials and daily practice. <i>Journal of Pathology</i> , 2020, 250, 667-684.	2.1	142
2	Male breast cancer in the United States: Treatment patterns and prognostic factors in the 21st century. <i>Cancer</i> , 2020, 126, 26-36.	2.0	82
3	Impact of histopathology, tumor-infiltrating lymphocytes, and adjuvant chemotherapy on prognosis of triple-negative breast cancer. <i>Breast Cancer Research and Treatment</i> , 2018, 167, 89-99.	1.1	74
4	A contemporary review of male breast cancer: current evidence and unanswered questions. <i>Cancer and Metastasis Reviews</i> , 2018, 37, 599-614.	2.7	63
5	Treatment of resistant metastatic melanoma using sequential epigenetic therapy (decitabine and) Tj ETQq1 1 0.784314 rgBT /Overlook 2014, 74, 691-697.	1.1	58
6	Folate receptor alpha expression associates with improved disease-free survival in triple negative breast cancer patients. <i>Npj Breast Cancer</i> , 2020, 6, 4.	2.3	49
7	Oxybutynin vs Placebo for Hot Flashes in Women With or Without Breast Cancer: A Randomized, Double-Blind Clinical Trial (ACCRU SC-1603). <i>JNCI Cancer Spectrum</i> , 2020, 4, pkr088.	1.4	46
8	The Landmark Series: Neoadjuvant Chemotherapy for Triple-Negative and HER2-Positive Breast Cancer. <i>Annals of Surgical Oncology</i> , 2021, 28, 2111-2119.	0.7	45
9	Management of hot flashes in women with breast cancer receiving ovarian function suppression. <i>Cancer Treatment Reviews</i> , 2017, 52, 82-90.	3.4	34
10	Comparison of Transarterial Liver-Directed Therapies for Low-Grade Metastatic Neuroendocrine Tumors in a Single Institution. <i>Pancreas</i> , 2014, 43, 219-225.	0.5	33
11	Characteristics and Spatially Defined Immune (micro)landscapes of Early-stage PD-L1 positive Triple-negative Breast Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 5628-5637.	3.2	32
12	Association between the use of surveillance PET/CT and the detection of potentially salvageable occult recurrences among patients with resected high-risk melanoma. <i>Melanoma Research</i> , 2017, 27, 335-341.	0.6	27
13	A clinical calculator to predict disease outcomes in women with triple-negative breast cancer. <i>Breast Cancer Research and Treatment</i> , 2021, 185, 557-566.	1.1	19
14	Analysis of patients without and with an initial triple-negative breast cancer diagnosis in the phase 3 randomized ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer. <i>Breast Cancer Research and Treatment</i> , 2022, 195, 127-139.	1.1	15
15	Luminal androgen receptor breast cancer subtype and investigation of the microenvironment and neoadjuvant chemotherapy response. <i>NAR Cancer</i> , 2022, 4, .	1.6	10
16	Estrogen receptor beta repurposes EZH2 to suppress oncogenic NF- κ B/p65 signaling in triple negative breast cancer. <i>Npj Breast Cancer</i> , 2022, 8, 20.	2.3	9
17	Nab-paclitaxel in patients with metastatic melanoma. <i>Expert Review of Anticancer Therapy</i> , 2015, 15, 1371-1377.	1.1	8
18	American Society of Clinical Oncology Sponsored Oncology Student Interest Groups in Latin America. <i>JCO Global Oncology</i> , 2020, 6, 1439-1445.	0.8	8

#	ARTICLE	IF	CITATIONS
19	A randomized, double-blind, placebo-controlled trial of testosterone for treatment of postmenopausal women with aromatase inhibitor-induced arthralgias: Alliance study A221102. Supportive Care in Cancer, 2021, 29, 387-396.	1.0	8
20	Supporting the Future of the Oncology Workforce: ASCO Medical Student and Trainee Initiatives. Journal of Oncology Practice, 2018, 14, 277-280.	2.5	7
21	Hypereosinophilic syndrome presenting as an unusual triad of eosinophilia, severe thrombocytopenia, and diffuse arterial thromboses, with good response to mepolizumab. Clinical Advances in Hematology and Oncology, 2013, 11, 317-9.	0.3	6
22	ASCO-Sponsored Oncology Student Interest Groups in the World. JCO Global Oncology, 2021, 7, 1586-1592.	0.8	4
23	Extravasation of oxaliplatin into the mediastinum: a case report and review of the literature. Clinical Advances in Hematology and Oncology, 2012, 10, 546-8.	0.3	4
24	Safety, efficacy, and tolerability of systemic therapies in male breast cancer: are there sex-specific differences?. Expert Opinion on Drug Safety, 2020, 19, 923-926.	1.0	3
25	Where Do We Stand on the Integration of PARP Inhibitors for the Treatment of Breast Cancer?. Current Oncology Reports, 2018, 20, 63.	1.8	2
26	A practical guide to endocrine therapy in the management of estrogen receptor-positive male breast cancer. Breast Cancer Management, 2021, 10, BMT59.	0.2	2
27	A B-wildering Case of Paraplegia: Cobalamin Deficiency. American Journal of Medicine, 2013, 126, 1045-1047.	0.6	1
28	Fit for Chemo: Nerves May Thank You. Journal of the National Cancer Institute, 2017, 109, djw208.	3.0	1
29	47-Year-Old Woman With Anemia and Thrombocytopenia. Mayo Clinic Proceedings, 2018, 93, 108-112.	1.4	0
30	N083E (Alliance): long-term outcomes of patients treated in a pilot phase II study of docetaxel, carboplatin, trastuzumab, and lapatinib as adjuvant therapy for early-stage HER2-positive breast cancer. Breast Cancer Research and Treatment, 2020, 182, 613-622.	1.1	0
31	Common Considerations in Male Breast Cancer Survivors. , 2021, , 319-328.		0